Taysha Gene Therapies, Inc. TSHA
Set alert
4.05 USD +0.05 +1.25%
As of Nov 3, 9:30 AM ET
4.05 Day range 4.08
3.46 52-week range 7.30
- YTD
- -26.36%
- 1 year
- -9.19%
- Open
- 4.08
- Prev close
- 4.00
- Mkt cap
- 1.32B
- Vol
- 2.01M
- Avg vol
- 3.54M
- EPS
- -0.41
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.05
- High
- 4.08
- Forward P/E
- -8.65
- Beta
- 1.31
- Short ratio
- 10.79
- Inst. own
- 94.28%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 4.82
- 200-d avg
- 5.32
- 1y target
- 13.00
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 13.00 +221.0% upside
Now 4.05
- Target (low)
- 9.00
- Target (mean)
- 13.00
- Target (high)
- 19.00
Ratings (0m) 13 13 buy · 0 hold · 0 sell
- Strong buy3
- Buy10
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 13
- 2 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.125 | -0.14 – -0.10 | -0.08748 | -42.9% | 618.18K | 0.0% | 4 |
| Next quarter | -0.1325 | -0.15 – -0.11 | -0.07317 | -81.1% | 1.30M | -76.3% | 4 |
| Current year | -0.474 | -0.58 – -0.38 | -0.3179 | -49.1% | 1.75M | -82.1% | 5 |
| Next year | -0.4625 | -0.53 – -0.43 | -0.474 | +2.4% | 19.65M | +1023.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 17, 2026 | Wolfe Research | Initiated | — | Outperform |
| Jul 21, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Jul 2, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Jun 30, 2026 | Needham | Maintained | Buy | Buy |
| Jun 30, 2026 | Baird | Maintained | Outperform | Outperform |
| Jun 23, 2026 | BMO Capital | Maintained | Outperform | Outperform |
| Jun 23, 2026 | B of A Securities | Maintained | Buy | Buy |
| Jun 23, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Jun 22, 2026 | Needham | Maintained | Buy | Buy |
| Apr 6, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 19, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Mar 19, 2026 | Needham | Maintained | Buy | Buy |
| Mar 3, 2026 | Needham | Reiterated | Buy | Buy |
| Jan 6, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Jan 5, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Nov 5, 2025 | Citizens | Maintained | Market Outperform | Market Outperform |
| Nov 5, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Oct 21, 2025 | Raymond James | Initiated | — | Strong Buy |
| Oct 17, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Oct 17, 2025 | Needham | Reiterated | Buy | Buy |
| Oct 2, 2025 | Baird | Maintained | Outperform | Outperform |
| Oct 2, 2025 | Needham | Maintained | Buy | Buy |
| Aug 13, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 13, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 12, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Jul 11, 2025 | B of A Securities | Initiated | — | Buy |
| Jul 1, 2025 | Needham | Reiterated | Buy | Buy |
| Jun 10, 2025 | Needham | Reiterated | Buy | Buy |
| Jun 3, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 2, 2025 | Needham | Reiterated | Buy | Buy |